166 related articles for article (PubMed ID: 24713546)
21. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy.
Ko MA; Zehong G; Virtanen C; Guindi M; Waddell TK; Keshavjee S; Darling GE
Ann Thorac Surg; 2012 Oct; 94(4):1094-102; discussion 1102-3. PubMed ID: 22939244
[TBL] [Abstract][Full Text] [Related]
22. Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications.
Menon MP; Khan A
J Clin Pathol; 2009 Nov; 62(11):978-85. PubMed ID: 19625289
[TBL] [Abstract][Full Text] [Related]
23. MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA profiling in ovarian cancer.
Iorio MV; Croce CM
Methods Mol Biol; 2013; 1049():187-97. PubMed ID: 23913217
[TBL] [Abstract][Full Text] [Related]
25. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
Sasaki N; Takano M; Kudou K; Kita T; Kikuchi Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():582-6. PubMed ID: 15535312
[No Abstract] [Full Text] [Related]
27. MicroRNAs and cancer: current state and future perspectives in urologic oncology.
Schaefer A; Jung M; Kristiansen G; Lein M; Schrader M; Miller K; Stephan C; Jung K
Urol Oncol; 2010; 28(1):4-13. PubMed ID: 19117772
[TBL] [Abstract][Full Text] [Related]
28. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
29. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of dicer expression in ovarian cancer tissues.
Pampalakis G; Diamandis EP; Katsaros D; Sotiropoulou G
Clin Biochem; 2010 Feb; 43(3):324-7. PubMed ID: 19782670
[TBL] [Abstract][Full Text] [Related]
31. MicroRNAs in ovarian carcinomas.
Dahiya N; Morin PJ
Endocr Relat Cancer; 2010 Mar; 17(1):F77-89. PubMed ID: 19903743
[TBL] [Abstract][Full Text] [Related]
32. Integrating multiple types of data to identify microRNA-gene co-modules.
Zhang S
Methods Mol Biol; 2013; 1049():215-29. PubMed ID: 23913219
[TBL] [Abstract][Full Text] [Related]
33. Current status on microRNAs as biomarkers for ovarian cancer.
Prahm KP; Novotny GW; Høgdall C; Høgdall E
APMIS; 2016 May; 124(5):337-55. PubMed ID: 26809719
[TBL] [Abstract][Full Text] [Related]
34. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
35. MicroRNAs in an oral cancer context - from basic biology to clinical utility.
Gorenchtein M; Poh CF; Saini R; Garnis C
J Dent Res; 2012 May; 91(5):440-6. PubMed ID: 22166582
[TBL] [Abstract][Full Text] [Related]
36. Beyond HPV: oncomirs as new players in cervical cancer.
Reshmi G; Pillai MR
FEBS Lett; 2008 Dec; 582(30):4113-6. PubMed ID: 19032954
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA expression profiling in prostate cancer.
Porkka KP; Pfeiffer MJ; Waltering KK; Vessella RL; Tammela TL; Visakorpi T
Cancer Res; 2007 Jul; 67(13):6130-5. PubMed ID: 17616669
[TBL] [Abstract][Full Text] [Related]
38. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer.
Li J; Liang S; Yu H; Zhang J; Ma D; Lu X
Gynecol Oncol; 2010 Dec; 119(3):543-8. PubMed ID: 20869762
[TBL] [Abstract][Full Text] [Related]
39. miRNA control of apoptotic programs: focus on ovarian cancer.
Mezzanzanica D; Canevari S; Cecco LD; Bagnoli M
Expert Rev Mol Diagn; 2011 Apr; 11(3):277-86. PubMed ID: 21463237
[TBL] [Abstract][Full Text] [Related]
40. Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis.
Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Hasanzadeh M; Parizadeh SMR; Hassanian SM; Rezaei-Kalat A; Aghabozorgi AS; Rahimi-Kakhki R; Zargaran B; Ferns GA; Avan A
Curr Drug Targets; 2019; 20(14):1447-1460. PubMed ID: 31284859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
